%0 Journal Article
%T 1,25-Dihydroxyvitamin D3 (1,25(OH)2D3) Signaling Capacity and the Epithelial-Mesenchymal Transition in Non-Small Cell Lung Cancer (NSCLC): Implications for Use of 1,25(OH)2D3 in NSCLC Treatment
%A Santosh Kumar Upadhyay
%A Alissa Verone
%A Suzanne Shoemaker
%A Maochun Qin
%A Song Liu
%A Moray Campbell
%A Pamela A. Hershberger
%J Cancers
%D 2013
%I MDPI AG
%R 10.3390/cancers5041504
%X 1,25-dihydroxyvitamin D 3 (1,25(OH) 2D 3) exerts anti-proliferative activity by binding to the vitamin D receptor (VDR) and regulating gene expression. We previously reported that non-small cell lung cancer (NSCLC) cells which harbor epidermal growth factor receptor ( EGFR) mutations display elevated VDR expression (VDR high) and are vitamin D-sensitive. Conversely, those with K-ras mutations are VDR low and vitamin D-refractory. Because EGFR mutations are found predominately in NSCLC cells with an epithelial phenotype and K-ras mutations are more common in cells with a mesenchymal phenotype, we investigated the relationship between vitamin D signaling capacity and the epithelial mesenchymal transition (EMT). Using NSCLC cell lines and publically available lung cancer cell line microarray data, we identified a relationship between VDR expression, 1,25(OH) 2D 3 sensitivity, and EMT phenotype. Further, we discovered that 1,25(OH) 2D 3 induces E-cadherin and decreases EMT-related molecules SNAIL, ZEB1, and vimentin in NSCLC cells. 1,25(OH) 2D 3-mediated changes in gene expression are associated with a significant decrease in cell migration and maintenance of epithelial morphology. These data indicate that 1,25(OH) 2D 3 opposes EMT in NSCLC cells. Because EMT is associated with increased migration, invasion, and chemoresistance, our data imply that 1,25(OH) 2D 3 may prevent lung cancer progression in a molecularly defined subset of NSCLC patients.
%K epithelial mesenchymal transition
%K vitamin D
%K 1
%K 25-dihydroxyvitamin D3
%K lung cancer
%K TGF¦Â
%U http://www.mdpi.com/2072-6694/5/4/1504